Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EFCAB10 antisense RNA 1 (EFCAB10-AS1) is a long noncoding RNA (lncRNA) classified as an antisense transcript, meaning it is transcribed from the DNA strand opposite to the coding sequence of the EFCAB10 gene. Like other antisense RNAs, it is presumed to regulate gene expression through RNA-RNA interactions or by influencing chromatin structure and epigenetic modification at its locus. However, there are currently no data supporting its direct role as a therapeutic target, involvement in specific diseases, drug interactions, or use as a biomarker. The gene is primarily noted as a member of the growing class of noncoding RNAs with gene regulatory potential, but little is currently known about its specific biological or pathological relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EFCAB10 antisense RNA 1 (EFCAB10-AS1).